Hair Restoration Candidacy Checklist: Who Is (and Isn't) a Good Fit for FUE

Candidacy is a physician's judgment, not a quiz — here is what goes into it

A hair transplant candidate is not identified by a checklist alone. Candidacy is a clinical decision that balances anatomy, pattern of loss, medical factors, expectations and long-term goals. The American Academy of Dermatology notes that two prerequisites must be met: a patient must have enough healthy donor hair available, and the recipient area must retain the ability to grow hair. Beyond those two foundations, many other variables — age and stability of loss, scalp conditions, medications, psychological readiness and the durability of donor follicles — inform whether surgery makes sense now, later or not at all.

True (2021) writes that candidacy depends on the age and stability of loss, the adequacy of donor supply, the pattern of hair loss itself, the realism of a patient's expectations and overall medical fitness. The International Society of Hair Restoration Surgery emphasizes that a patient's reasons and expectations must be placed in a realistic context before surgery. Dr. Charles Pereyra, MD, a board-certified emergency physician and member of the ISHRS, evaluates each of these dimensions personally during the Follicular Health Assessment at Springs, and he performs the Micrograft FUE procedure himself — extraction and placement are not delegated.

This page outlines the factors that typically place a patient in the strong-fit, worth-a-conversation or wait-and-reassess category. It is not a self-diagnosis tool; it is a guide to the reasoning a physician applies when deciding whom to accept, whom to defer and whom to counsel toward medical management first.

The checklist at a glance

The table offers a general framework. Individual cases fall across categories, and a physician weighs the whole picture rather than a single row.

Age, stability and the case for stabilizing first

True (2021) writes that very young patients with rapidly progressing loss are usually asked to stabilize the pattern before surgery. Hair loss that accelerates after a procedure can leave transplanted grafts in a sea of continued thinning, and the finite donor supply may be consumed before the final pattern is known. Many surgeons reassess after a period on finasteride or minoxidil to observe whether progression slows.

Kaufman and colleagues (1998) reported two-year randomized placebo-controlled trials of finasteride 1 mg in 1,553 men aged 18 to 41; the finasteride group showed increased hair counts versus placebo, while the placebo group experienced continued progression. Olsen and colleagues (2002) found in a 48-week randomized trial that 5% topical minoxidil outperformed 2% minoxidil and placebo on hair count in men. Lucky and colleagues (2004) demonstrated in a randomized placebo-controlled trial that both 5% and 2% topical minoxidil beat placebo on hair count at 48 weeks in women with female-pattern hair loss. These medications do not address every case, and individual responses vary, but they provide a window to observe stability.

The American Academy of Dermatology notes that a dermatologist may ask a patient to start a hair-loss medicine first. The rationale is twofold: slowing native loss reduces demand on the donor area over time, and observing the pattern on medication helps distinguish rapid early loss from a more gradual trajectory. A patient in the mid-twenties with aggressive progression may be an excellent hair transplant candidate at age 30 after a few years of medical stabilization.

Pattern and donor supply: Norwood-type loss versus diffuse unpatterned alopecia

Patterned loss — receding temples and vertex thinning in men following the Norwood scale, or widening central part in women following the Ludwig scale — indicates that the donor area in the back and sides of the scalp is genetically resistant to miniaturization. Grafts harvested from that zone are expected to retain their growth characteristics when moved to the recipient area. Diffuse unpatterned alopecia (DUPA), by contrast, involves miniaturization across the entire scalp, including the donor zone itself.

Spindler and colleagues (2026) offer a reappraisal of DUPA and note that when the donor zone is miniaturizing, transplanted hair may not prove durable. A physician examines donor density, caliber and the presence of miniaturized hairs under magnification. If the donor area shows widespread thinning rather than stable resistance, surgery may transfer follicles that will not prove durable rather than follicles that retain their growth characteristics.

Konior (2024) writes that patient selection for FUE versus linear strip harvesting depends on hair characteristics, donor laxity, desired hairstyle and session size. Coarse-caliber hair provides more coverage per graft than fine hair. Dark hair on pale scalp shows higher contrast than blonde hair on fair skin, and curl can create an illusion of density. A patient with fine, straight, low-contrast hair may need more grafts to achieve a given cosmetic result, and donor supply must be adequate for both the initial procedure and any future sessions.

The ISHRS 2025 Practice Census, a survey of member activity in 2024, found that the average FUE case involved 2,262 grafts and the average strip case 2,100 grafts. Those figures provide context for planning, but an individual session size depends on donor capacity, recipient needs and the balance between coverage and reserve. The American Hair Loss Association's long-term planning guidance emphasizes that donor hair is finite and that medical care to preserve native hair reduces demand on the donor area over time.

Scalp conditions, medical factors and medications a physician reviews

Active scalp disease — untreated seborrheic dermatitis, psoriasis, fungal infection or an inflammatory scarring alopecia — typically requires management before elective surgery. Scarring alopecias that have burned out and left stable scar tissue may be addressable once the inflammatory phase has passed, but individual responses vary and a dermatologist's assessment is part of the workup.

A physician reviews medications that affect bleeding risk, immune function or wound response. Smoking impairs microcirculation and graft survival; many surgeons ask patients to stop smoking well before and after the procedure. A history of keloid formation, particularly on the scalp, raises concern about scarring in the donor area. Uncontrolled medical conditions — such as poorly managed diabetes or a bleeding disorder — may need optimization or clearance from a specialist before elective surgery proceeds.

The American Academy of Dermatology notes that blood tests or a scalp biopsy are sometimes needed to clarify the diagnosis. Iron deficiency, thyroid dysfunction, autoimmune markers or hormonal imbalances can contribute to hair loss, and addressing those factors may improve candidacy or provide an alternative to surgery. The goal is not to rule out every patient with a medical history; it is to identify what needs attention first.

Expectations, timeline and the psychology of the decision

The ISHRS consumer education materials state that a patient's reasons and expectations must be placed in a realistic context before surgery. The American Academy of Dermatology writes that complete restoration may be unrealistic, but achieving fuller hair can be the goal. That distinction — fuller versus complete — separates an achievable outcome from a promise that surgery cannot deliver.

Dhami (2021) discusses the psychology of hair-loss patients and the importance of counseling. Hair loss affects self-image, social confidence and occupational perception, and those motivations are valid. The ISHRS 2025 Practice Census found that the most common patient-stated reasons for surgery were to become or feel more attractive (90.0%) and to appear younger to compete in the workplace (62.7%). At the same time, Tan and colleagues (2025) reviewed the psychological dimensions of hair restoration and noted the importance of screening for body dysmorphic disorder. A patient whose distress is out of proportion to the visible loss, or who expresses certainty that a fuller hairline will resolve unrelated life problems, may benefit from psychological support before or instead of surgery.

Timeline tolerance is part of psychological readiness. Transplanted grafts typically shed within two to three weeks of the procedure, then re-enter a growth phase over the following three to four months. Visible improvement emerges gradually, and final density is usually assessed at twelve months. Individual responses vary, and some patients see earlier or later maturation. A patient who needs visible change within weeks to meet a specific event or deadline is not a good fit for a process that unfolds over a year.

The American Academy of Dermatology notes that surgery usually takes four to eight hours under local anesthesia with the patient awake. Knowing what the day involves — duration, positioning, the sensation of local anesthetic injections, postoperative instructions — helps a patient decide whether the experience aligns with tolerance and schedule.

When the answer is 'not yet' — and what the alternatives are

Declining a patient is not a failure of the consultation; it is part of the process. A physician may recommend deferring surgery and revisiting candidacy after a period of medical management. Finasteride and minoxidil, supported by the trials of Kaufman (1998), Olsen (2002) and Lucky (2004), can slow progression and in some cases modestly increase hair count. Vañó-Galván and colleagues (2021) reported a multicenter series of 1,404 patients on low-dose oral minoxidil; hypertrichosis was the most common adverse effect, discontinuation for side effects was uncommon, and oral minoxidil is used off-label for hair loss.

Springs offers a Peptide + Lifestyle Program that addresses hormonal balance, nutrient status, inflammation and metabolic factors that influence follicle function. The Stem Cell Exosome Scalp Protocol is investigational, not FDA approved to treat any disease, and early studies suggest that exosomes may modulate inflammation and signaling pathways in the follicle microenvironment; individual responses vary, published findings are preliminary, and the intervention is offered as part of ongoing research rather than as a replacement for established medical care.

Ongoing Growth Support — which may include compounded topical formulations, low-level light devices, microneedling protocols and nutritional counseling — provides options for patients who are not ready for surgery or who wish to support native hair alongside a surgical plan. Reassessment after six to twelve months of medical management often clarifies whether the pattern has stabilized and whether donor supply is adequate.

The Follicular Health Assessment at Springs

The Follicular Health Assessment is the consultation during which Dr. Charles Pereyra, MD, evaluates donor density and caliber under magnification, maps the pattern of loss, reviews medical history and medications, discusses goals and timeline, and decides candidacy personally. Springs has performed more than 7,000 procedures, and the assessment draws on that experience to forecast donor yield, plan graft distribution and set realistic expectations.

The ISHRS consumer advocacy page advises that patients should ask who will evaluate their hair loss, who will perform each part of the surgery and what their licensure and training is, whether anyone not licensed by the state will make incisions or harvest grafts, and whether everyone is covered by malpractice insurance. At Springs, Dr. Pereyra performs both the extraction and placement phases of the Micrograft FUE procedure himself; those steps are not delegated to a physician assistant or technician.

The ISHRS also states that any incision beyond the most superficial depth forms a scar in hair restoration. FUE creates small circular scars at each extraction site, typically less visible than the linear scar of strip harvesting but present nonetheless. A January 31, 2020, position of the New York State Board for Professional Medical Conduct noted that hair restoration surgery should only be performed by qualified physicians.

Springs quotes one all-in price at the consultation; that figure covers the procedure, anesthesia, facility, follow-up visits and the Ongoing Growth Support plan. The consultation itself begins with a virtual visit, during which Dr. Pereyra reviews photos, discusses medical history and outlines whether an in-person assessment is the next step. For out-of-state patients, the travel program includes virtual consultation, a written care plan, travel to one of the five clinics for the procedure, an in-person recovery check before flying home, and remote follow-up.

The five clinic locations are Aventura (Miami), Florida at 2820 NE 214th St Suite 801, Aventura FL 33180; Los Angeles, California (Arts District) at 420 E 3rd St Suite 705, Los Angeles CA 90013; Austin, Texas at 8700 Menchaca Rd Suite 602, Austin TX 78748; Atlanta, Georgia (Midtown) at 1800 Peachtree St NE Suite 660, Atlanta GA 30309; and New York, New York (NoMad) at 245 5th Ave 3rd Floor Suite 307, New York NY 10016. Every location shares the same phone line: (888) 503-4482.

Frequently asked questions

Is there a minimum age for FUE?

There is no regulatory minimum, but most surgeons prefer patients to be in their late twenties or older so that the pattern of loss has declared itself. True (2021) notes that very young patients with rapidly progressing loss are usually asked to stabilize first. A patient under age 25 may be an excellent hair transplant candidate, but many physicians recommend a period on finasteride or minoxidil to observe whether the rate of loss slows before committing donor supply. Age alone does not disqualify; stability and donor adequacy for long-term planning are the deciding factors.

Can a patient with diffuse thinning have FUE?

It depends on the pattern. Diffuse thinning that follows a recognizable Norwood or Ludwig pattern — meaning the donor area remains dense and resistant — can be a good fit. Diffuse unpatterned alopecia, in which the donor zone itself shows miniaturization, is more problematic. Spindler and colleagues (2026) write that when the donor area is thinning, transplanted grafts may not prove durable. A physician examines donor density and caliber under magnification during the assessment. Some patients with diffuse thinning are better served by medical management or investigational protocols that address the entire scalp rather than redistributing a finite donor supply.

Does a patient need to be on finasteride or minoxidil before having FUE?

Not in every case, but many surgeons strongly recommend it. The American Hair Loss Association writes that medical care to preserve native hair reduces demand on the donor area over time. Finasteride and minoxidil do not restore the hair that has been lost, but the evidence from Kaufman (1998) and Olsen (2002) shows that they can slow progression and in some cases modestly increase count. A patient who declines medication may still be a candidate if the pattern is stable and donor supply is adequate, but ongoing native loss after surgery can leave transplanted grafts isolated, and the donor reserve may be needed for future sessions.

What disqualifies someone from FUE?

Active scarring alopecia in an inflammatory phase, untreated scalp infections, uncontrolled bleeding disorders, a history of widespread keloid formation on the scalp, and inadequate donor supply relative to the area of loss are common reasons to defer or decline. Unrealistic expectations — such as a belief that surgery will restore a teenage hairline or that transplanted hair is immune to all future loss — also disqualify, because the outcome will not meet the patient's internal standard no matter how technically successful the procedure. The ISHRS emphasizes that expectations must be realistic before surgery proceeds. Psychological factors, including body dysmorphic disorder, may require evaluation and support first.

How is the donor area assessed during the consultation?

A physician examines the back and sides of the scalp under magnification to measure hair density (follicular units per square centimeter), caliber (the diameter of each hair shaft), the ratio of single-hair to multi-hair units, and the presence of miniaturized hairs. Scalp laxity — how much the skin can stretch — informs how tightly the donor area can be harvested without visible thinning. Color contrast between hair and skin, curl and the patient's hairstyle preferences also factor into the plan. Konior (2024) writes that these characteristics influence the choice between FUE and strip harvesting and the graft count needed to achieve a given cosmetic result. The assessment is not a single measurement; it is a layered evaluation of anatomy, reserve and long-term goals.

About the author: Dr. Charles Pereyra, MD, is a board-certified emergency physician (NewYork-Presbyterian Brooklyn Methodist), a member of the International Society of Hair Restoration Surgery (ISHRS), and the physician who personally performs Micrograft FUE procedures at Springs Rejuvenation Hair.

Medical disclaimer: Stem cell and exosome therapy is not an FDA approved therapy and is considered to be in the experimental stages; it is not FDA approved to treat any disease. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Reviewed for medical accuracy by Dr. Charles Pereyra, MD, Medical Director, Springs Rejuvenation.